Immunome promotes Max Rosett to EVP, Operations and Interim CFO; grants option for 175k shares

Immunome Inc.

Max Rosett promoted from SVP, Operations and Interim CFO to EVP, Operations and Interim CFO effective Jan 31, 2024.
Annual base salary increased to $425,000.
Granted option to purchase 175,000 shares at $16.57 per share (closing price on grant date).
Option vests 25% on one-year anniversary, then 36 equal monthly installments.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change (interim)

Max Rosett

Executive Vice President, Operations and Interim Chief Financial Officer

IMNM · Immunome Inc.

Effective: 2024-01-31
Filed: February 1, 2024, 6:59 PM ET

On January 31, 2024, the Board of Directors (the “Board”) of Immunome, Inc. (the “Company”) promoted Max Rosett, the Company’s Senior Vice President, Operations and Interim Chief Financial Officer to Executive Vice President, Operations and Interim Chief Financial Officer (the “Promotion”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Max Rosett changed role as Executive Vice President, Operations and Interim Chief Financial Officer at Immunome Inc..

Action: promoted
Role: Executive Vice President, Operations and Interim Chief Financial Officer

Exact text from the filing

On January 31, 2024, the Board of Directors (the “Board”) of Immunome, Inc. (the “Company”) promoted Max Rosett, the Company’s Senior Vice President, Operations and Interim Chief Financial Officer to Executive Vice President, Operations and Interim Chief Financial Officer (the “Promotion”).

View on SEC.gov

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-009012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.